StockNow
Calendar
Log in
U.S. Markets

AbbVie (ABBV) announces positive topline results from the Phase 3 INTREPID study evaluating the safety and efficacy of lutikizumab in adults and adolescents with moderate to severe hidradenitis suppurativa

StockNow breaking-news AI analysis

AbbVie announced positive INTREPID topline results for lutikizumab, but the supplied record contains no efficacy or safety figures or further study details.

1 stocks
ABBVABBVIE INC.$284.46Current price

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
Geopolitics

Israeli PM Netanyahu says "I will inform [US President] Trump of what we intend to do, but I will not ask him for the green light to strike Iran", Al Arabiya reports

Geopolitics

[MARKET UPDATE] WTI tops USD 100/bbl as punchy comments from Iran overnight get a wider airing

U.S. Markets

Some US banks are reportedly detecting unauthorised AI agents operating within accounts, Axios reports citing sources

MSBACJPM